Clinical Characteristics, Investigations and Treatment in Children with Chronic Urticaria: An Observational Study

• Published in: Medicina (Kaunas, Lithuania) Vol. 60; no. 5; p. 704
• Main Authors: Buono, Enrico Vito, Giannì, Giuliana, Scavone, Sara, Caffarelli, Carlo
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.05.2024
• Subjects: Acetates - administration & dosage; Acetates - therapeutic use; Adolescent; Allergens; allergic disease; Angioedema; Anti-Allergic Agents - administration & dosage; Anti-Allergic Agents - therapeutic use; Antibodies; Biopsy; Celiac disease; Child; Child, Preschool; children; Chronic Disease; chronic urticaria; Chronic Urticaria - drug therapy; Cyclopropanes - therapeutic use; Female; Food allergies; Glucocorticoids - therapeutic use; Histamine; Histamine H1 Antagonists - administration & dosage; Histamine H1 Antagonists - therapeutic use; Humans; Infant; Infant, Newborn; Male; Medical research; Medicine, Experimental; Omalizumab; Omalizumab - therapeutic use; Pediatrics; Quinolines - administration & dosage; Quinolines - therapeutic use; Sulfides; Thyroid gland; Urticaria; Urticaria - drug therapy; urticaria diagnosis; urticaria treatment; Italy; chronic urticaria; urticaria treatment; urticaria diagnosis; omalizumab; allergic disease; children
• ISSN: 1648-9144; 1010-660X; 1648-9144
• DOI: 10.3390/medicina60050704

The guidelines for chronic urticaria in children contain recommendations that are often based on adult studies. The diagnostic pathway has not been standardized and the effectiveness of anti-H1, omalizumab, montelukast, and systemic glucocorticoids is rarely reported in the pediatric population. There is a wide variation in the rate of remission of chronic urticaria between studies. The aim of this study is to enhance our understanding of pediatric chronic urticaria. This study enrolled 37 children with chronic urticaria aged from 0 to 18 years. Demographic parameters, medical history, clinical features, laboratory data and treatment information were collected. Children were treated with the recommended dosage of second-generation H1-antihistamines, which was increased by up to twofold. Omalizumab was added for refractory anti-H1 patients. A three-day course with systemic glucocorticoids was administered for severe exacerbations. Montelukast was administered to some children. : Wheals without angioedema were common. Chronic urticaria was spontaneous in 32 children (86.48%), inducible in 2 (5.41%), induced by a parasite in 1 and vasculitic in 2. Treatment of the potential causes of chronic urticaria was of no benefit, except for eradication of Dientamoeba fragilis. Chronic urticaria was resolved within three years in 45.9% of cases. Allergic diseases were present in nine children (24.32%) and autoimmune diseases were present in three (8.11%). All children were treated with anti-H1 at the licensed dose or at a higher dose. A partial or complete response to anti-H1 was observed in 29 (78.38%) patients. Montelukast showed no benefit. All children treated with omalizumab responded. Systemic glucocorticoids were successfully used to treat exacerbations. Our findings indicate that laboratory tests should not be routinely performed in children with chronic urticaria without clinical suspicion. However, comorbidities such as thyroid autoimmune disease and coeliac disease are suggested to be monitored over the chronic urticaria course. These clinical conditions could be diagnosed from the diagnostic framework of chronic urticaria. Increasing the dosage of anti-H1 and omalizumab was effective in children resistant to standard treatment but we still need further studies to generate a standard patient-centered treatment.